Abstract:Background & aims Nonalcoholic fatty liver disease (NAFLD) is a dynamic spectrum of chronic metabolic liver disease and ranges from simple steatosis to nonalcoholic steatohepatitis (NASH). However, the molecular mechanisms underlying steatosis-to-NASH progression remain incompletely understood. Methods In the present study, we investigated the profiling changes of MicroRNAs and identified miR-145a-5p as an important checkpoint in this process. In vivo loss-of-function and gain-of-function studies were performed to explore the role of miR-145a-5p and Nr4a2 in NASH progression. RNA-Sequencing and bioinformatic analysis were used to investigate the target of miR-145a-5p. Results Suppression of miR-145a-5p in the liver activated hepatic inflammation, liver injury and fibrosis in steatotic mice, whereas its restoration markedly attenuated diet-induced NASH pathogenesis. Mechanistically, miR-145a-5p was able to downregulate the nuclear receptor Nr4a2 to inhibit the expression of NASH-associated genes. Similarly, Nr4a2 overexpression promoted steatosis-to-NASH progression while liver-specific Nr4a2 knockout mice were protected from diet-induced NASH. Of potential clinical significance, the miR-145a-5p/Nr4a2 regulatory axis was also confirmed in human primary hepatocytes. Besides, expression level of miR-145a-5p was reduced and Nr4a2 was increased in the livers of NASH patients. Their expression levels were significantly correlated with hepatic pathological features. Conclusions Our findings highlight the role of miR-145a-5p/Nr4a2 regulatory axis in steatosis-to-NASH progression, suggesting that either supplementation of miR-145a-5p or pharmacological inhibition of Nr4a2 in hepatocytes may provide a promising therapeutic approach for treating NASH. Impact and implications Nonalcoholic fatty liver disease (NAFLD) is a dynamic spectrum of chronic liver disease ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). Unfortunately, there are currently no approved drugs for NASH. Our current study identified miR-145a-5p as a novel regulator that inhibits steatosis-to-NASH progression. We found that miR-145a-5p was able to downregulate the nuclear receptor Nr4a2 to suppress the expression of NASH-associated genes. The differentially expression of miR-145a-5p and Nr4a2 was further confirmed in patients with NASH, raising the possibility that supplementation of miR-145a-5p or suppression of Nr4a2 in hepatocytes might provide novel strategies for treating NASH.

Effect of Mirna-10b in Regulating Cellular Steatosis Level by Targeting Ppar-Alpha Expression, A Novel Mechanism for the Pathogenesis of Nafld

Effect Of Mir-34a In Regulating Steatosis By Targeting Ppar Alpha Expression In Nonalcoholic Fatty Liver Disease

Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease

Aberrant Hepatic Microrna Expression in Nonalcoholic Fatty Liver Disease

MiR-103-3p Promotes Hepatic Steatosis to Aggravate Nonalcoholic Fatty Liver Disease by Targeting of ACOX1

Potential roles of miR-152 in nonalcoholic fatty liver disease by the bioinformatic analysis

Effect of Mir-146 Targeted Hdmcp Up Regulation in the Pathogenesis of Nonalcoholic Steatohepatitis

MicroRNA-376b-3p ameliorates nonalcoholic fatty liver disease by targeting FGFR1 and regulating lipid oxidation in hepatocytes

Transition from hepatic steatosis to steatohepatitis: unique microRNA patterns and potential downstream functions and pathways.

Long Non-Coding Rna Profiling In A Non-Alcoholic Fatty Liver Disease Rodent Model: New Insight Into Pathogenesis

Downregulation of microRNA-145a-5p promotes steatosis-to-NASH progression through upregulation of Nr4a2

MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease.

Upregulation of miR-181a impairs lipid metabolism by targeting PPARα expression in nonalcoholic fatty liver disease.

Lipotoxic Effect of P21 on Free Fatty Acid-Induced Steatosis in L02 Cells

Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA

MicroRNA-20a-5p Ameliorates Non-alcoholic Fatty Liver Disease via Inhibiting the Expression of CD36

MicroRNA-451 and Genistein Ameliorate Nonalcoholic Steatohepatitis in Mice.

Differential Expression of Micrornas in Mouse Liver under Aberrant Energy Metabolic Status

RMRP inhibition prevents NAFLD progression in rats via regulating miR-206/PTPN1 axis

Targeting Hepatic Mir-221/222 for Therapeutic Intervention of Nonalcoholic Steatohepatitis in Mice

Lnc-Hc Ameliorates Steatosis by Promoting Mir-130B-3p Biogenesis and the Assembly of an RNA-induced Silencing Complex.